Earnings Call Transcripts
Access detailed transcripts and key takeaways from company earnings calls
All Earnings Calls
CareDx Q3 2025 Earnings Call - Robust 21% Revenue Growth and Strategic Advances Amid Flat Transplant Volumes
CareDx posted strong third-quarter 2025 results with revenue hitting $100.1 million, up 21% year-over-year, led by record volumes across testing services, patient and digital solutions, and lab produc...
- CareDx delivered record third-quarter revenue of $100.1 million, a 21% increase year-over-year, and adjusted EBITDA of $15.3 million, more than doubling prior year.
- Testing services revenue grew 19% to $72.2 million driven by 13% test volume growth across heart, kidney, and lung transplant monitoring.
- Patient and digital solutions revenue rose 30% to $15.4 million, reflecting higher adoption of transplant pharmacy and digital tools.
- +7 more takeaways
Veracyte 3Q 2025 Earnings Call - Decipher Prostate Test Drives Record Profitability and Accelerated Growth Outlook
Veracyte delivered a strong third quarter in 2025, reporting a 14% revenue increase to $132 million driven by a 26% volume growth in its Decipher prostate cancer test and 13% growth in the Affirma thy...
- Veracyte’s Q3 revenue rose 14% year-over-year to approximately $132 million, driven by strong volume growth in core tests.
- Decipher prostate cancer test volumes grew 26% year-over-year, marking 14 consecutive quarters with over 25% growth.
- Affirma thyroid test volume grew 13%, supported by new account wins and increased utilization per customer.
- +13 more takeaways
NGL Energy Partners Q2 2026 Earnings Call - Water Solutions Segment Drives Record Growth and EBITDA Boost
NGL Energy Partners reported a solid Q2 2026, highlighted by record water volumes and a 30% jump in Grand Mesa pipeline volumes. Consolidated Adjusted EBITDA rose 12% year-over-year to $167.3 million,...
- Q2 2026 consolidated Adjusted EBITDA climbed 12% year-over-year to $167.3 million, mainly driven by Water Solutions.
- Water Solutions segment adjusted EBITDA increased 18% to $151.9 million, with physical disposal volumes growing 4% to 2.8 million barrels per day.
- Total paid disposal volumes, including deficiency volumes, rose 14% to 3.15 million barrels per day compared to prior year quarter.
- +11 more takeaways
comScore Q3 2025 Earnings Call - Cross-Platform Growth Offset by Large Client Shift, New Product Momentum Key
comScore reported a modest revenue increase to $88.9 million in Q3 2025, driven by strong double-digit growth in local and cross-platform measurement offerings. However, a notable strategy shift from ...
- Q3 2025 revenues reached $88.9 million, a slight 0.5% increase year-over-year.
- Local TV measurement showed strong double-digit revenue growth, driven by new business and renewals.
- Cross-platform revenue grew 20.2% despite the headwind from a strategic shift by a large retail media client.
- +10 more takeaways
Rapid7 Q3 2025 Earnings Call - Strategic Transition to AI-Powered MDR Slows ARR Growth Momentum
Rapid7 reported a 2% year-over-year increase in ARR to $838 million and a 2% revenue growth to $218 million in Q3 2025, modestly beating guidance amidst a challenging large-deal pipeline environment. ...
- Rapid7’s ARR reached $838 million in Q3 2025, growing 2% year-over-year, with revenue of $218 million also up 2%.
- Operating income was $37 million, beating guidance, aided by business leverage and operational timing.
- Free cash flow remained strong at $30 million for the quarter and $98 million year-to-date.
- +11 more takeaways
Clean Energy Fuels Q3 2025 Earnings Call - Steady Downstream Growth and Upstream RNG Ramp-Up with Cautious Outlook
Clean Energy Fuels reported solid Q3 2025 results with $106 million revenue and $17 million Adjusted EBITDA, maintaining their raised 2025 guidance. Their downstream fueling business showed steady per...
- Clean Energy Fuels posted $106 million revenue and $17 million Adjusted EBITDA in Q3 2025, aligning with their raised guidance.
- The downstream fueling business remains stable with strong contributions from transit and refuse fleets, totaling over 300 fueling sites and 140 refuse customers.
- Heavy-duty trucking is identified as the largest downstream growth opportunity amid challenging freight rates and regulatory uncertainty.
- +12 more takeaways
Astronics Corp Q3 2025 Earnings Call - Building Momentum with Record Volume, Margin Expansion, and Strategic Acquisitions
Astronics Corp reported a strong Q3 2025 with revenue at $211.4 million, marking their second highest quarterly sales ever, driven by broad-based demand and improved operational efficiencies. Aerospac...
- Q3 revenue reached $211.4 million, just shy of the company record, showing broad demand and improved production efficiency.
- Aerospace segment led with $192.7 million sales and 16.2% operating margin, driving overall profitability.
- Test segment sales declined year-over-year to $18.7 million but improved QoQ, nearing break-even operating margin due to cost reduction efforts.
- +17 more takeaways
Astera Labs Q3 2025 Earnings Call - Scaling AI Infrastructure Connectivity with Scorpio X and Optical Ventures
Astera Labs delivered a robust Q3 2025 with revenues of $230.6 million, marking a 104% year-over-year increase and robust growth across its Scorpio, Aries, and Taurus product lines targeting AI scale-...
- Q3 2025 revenue reached $230.6 million, up 104% year-over-year and 20% quarter-over-quarter driven by broad-based growth in Scorpio, Aries, and Taurus product lines.
- Scorpio P Series advanced volume ramp with leading hyperscalers and new design wins across multiple AI platforms; Scorpio X Series shipping initial production volumes, expected to ramp significantly in 2026.
- Aries PCIe Gen 6 retimers, the industry’s first and only, contributed robust growth exceeding 20% of Q3 revenues, underpinning PCIe 6 acceleration adoption in AI racks.
- +7 more takeaways
Day One Biopharmaceuticals 3Q 2025 Earnings Call - OJEMDA Drives Strong Commercial Momentum and Raised Full-Year Guidance
Day One Biopharmaceuticals reported a robust third quarter in 2025, highlighted by 15% sequential growth in OJEMDA net product revenue to $38.5 million and accelerating new patient starts and prescrip...
- OJEMDA net product revenue reached $38.5 million in Q3, a 15% increase quarter-over-quarter, reflecting the strongest quarter so far in 2025.
- New patient starts accelerated nearly 20%, and total prescriptions grew 18% this quarter, indicating strong uptake and growing physician adoption.
- Two-year FIREFLY-1 data included in OJEMDA label demonstrate reversible growth velocity decreases and increased median duration of response from 13 to 18 months, boosting clinical confidence.
- +12 more takeaways
Revolve Group Q3 2025 Earnings Call - Strategic Margin Focus Amid Moderate Sales Growth
Revolve Group reported a solid Q3 2025, delivering a 4% year-over-year increase in net sales alongside a remarkable 45% surge in adjusted EBITDA to $25 million, marking its highest ever for a third qu...
- Revolve Group's Q3 2025 net sales grew 4% year-over-year to $296 million, with Revolve segment up 5% and Forward segment up 3%.
- Adjusted EBITDA surged 45% year-over-year to $25 million, the highest for any third quarter in the company's history.
- Gross margin expanded by nearly 350 basis points to 54.6%, exceeding guidance despite tariff pressures and broad input cost inflation.
- +13 more takeaways